

19.

Brain metastases

Background

This is a heterogeneous population of patients with diverse underlying histologies, differences in disease burden outside the central nervous system (CNS) and differing systemic therapy options. As such, it is helpful to classify patients according to a simplified system. The original recursive partitioning analysis (RPA) based system of the Radiation Therapy Oncology Group (RTOG) is simple and robust, but has now been replaced by the Graded Prognostic Assessment (GPA) and the disease-specific GPA (dsGPA).^{1–9} These prognostic scores continue to evolve, and still do not fully reflect the latest systemic therapies.^{5,10}

Patients can be divided into three groups according to disease specific factors, but in general these three of importance:

- Karnofsky Performance Status (KPS) (at least 70)
- Control of the primary tumour
- Brain as the only site of disease.

Patients who fail to meet all three criteria tend to have a very poor prognosis, and may not benefit from treatment.

The regimens most commonly used for the whole-brain radiotherapy (WBRT) treatment of cerebral metastases are 30 Gy in ten fractions over two weeks or 20 Gy in five fractions over one week. For patients with limited disease, other approaches, including gamma knife or stereotactic radiosurgery (SRS) and intraoperative radiotherapy are feasible. The following discussion draws heavily on a systematic review performed as part of the Cancer Care Ontario programme in evidence-based care.¹¹

Solitary or oligo-metastases

The evidence from one systematic review and three randomised trials suggests benefit from adding surgery to whole brain radiotherapy (WBRT) for patients of good performance status with a solitary metastasis (Level 1a).^{11–14} Stereotactic radiosurgery (SRS) added to WBRT offers a survival benefit for selected patients with a solitary metastasis, as well as for patients of RPA Class I with up to three metastases.¹⁵ In patients with up to three brain metastases and KPS ≥ 70 , adding SRS to WBRT improves functional independence and reduces steroid requirements at six months (Level 1b).^{15,16}

Patients with more than three brain metastases were not included in these trials. Moreover, it is recognised that the number of brain metastases detected on magnetic resonance imaging (MRI) is technique dependent. For small-volume disease, a prospective observational study (Level 2+) in patients with up to ten metastases (largest <10 centimetres³ [cm³], total volume ≤ 15 cm³) has suggested that overall survival is equivalent for patients with five to ten as compared to two to four metastases and therefore the number of metastases treated using SRS without WBRT may not correlate with outcome.^{16,17} Several retrospective studies (Level 3) have shown that the total volume of brain metastases correlates better with outcomes, including local control, distant intracranial relapse and overall survival after SRS than number of brain metastases.^{7,16,18–20}

Recommendations

Solitary metastases:

Surgery or SRS:

Lesion diameter

<20 millimetres (mm) – 24 Gy single dose (Grade B)

21–30 mm – 18 Gy single dose (Grade B)

31–40 mm – 15 Gy single dose (Grade B)

Multiple metastases up to total volume of 20 cm³ with good performance status (Karnofsky Performance Status ≥ 70) and controlled extra-cranial disease:²

SRS:

Lesion diameter

<20 mm – 24 Gy single dose (Grade C)

21–30 mm – 18 Gy single dose (Grade C)

31–40 mm – 15 Gy single dose (Grade C)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-based Medicine.¹⁶

Whole-brain radiotherapy with SRS

While WBRT was part of the initial treatment of patients in the above-mentioned trials of surgery or SRS, three randomised trials have now investigated the addition of WBRT to surgery or SRS for patients with one to four brain metastases.^{21–24} A meta-analysis of these trials has also been published.²⁵ Adding WBRT to local therapy by surgery or SRS appears to improve intracranial control and reduce neurological deaths without influencing overall survival (Level 1a).¹⁶ However, the addition of WBRT to SRS has been shown in one small randomised trial to result in a significantly greater risk of neurocognitive deficits at three months, and for this reason many groups now choose to defer WBRT.²⁶ Post-treatment MRI surveillance was used in all three trials and is recommended by some expert groups, but high-level evidence about the value of MRI surveillance is lacking.²⁷ Avoidance of the hippocampus has been suggested as a method to limit the neurocognitive effects of WBRT, but as yet there is little data to support this.

Recommendation

WBRT with SRS:

30 Gy in 10 fractions over 2 weeks (Grade A)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-based Medicine.¹⁶

Adjuvant postoperative SRS and hypofractionation

While WBRT reduces the risk of intra-cranial relapse postoperatively, the lack of impact on overall survival has led to the exploration of SRS to the stereotactic cavity.¹⁶ In line

with previous data, radiotherapy after surgery reduces the risk of intra-cranial relapse, and radiotherapy restricted to the tumour bed appears to be non-inferior to whole brain radiotherapy.^{28,29} However, technical problems and optimal dose and fractionation schedules are as yet unclear. For patients with larger metastases >2 cm diameter, there has been interest in hypofractionated SRS, delivered as 3–5 fractions. As yet, there is no data to support an optimal dose-fractionation schedule.

Whole-brain radiotherapy for multiple metastases

Background

Several randomised trials have compared different radiotherapy regimens for patients with multiple cerebral metastases. Most have used 30 Gy in ten fractions as the control arm and have compared this regimen to either higher or lower doses.^{30–33} Only one small study of 70 patients has compared the six-month survival rate after 30 Gy in ten fractions to that after 20 Gy in five fractions. There was no significant difference.²⁶ A Radiation Therapy Oncology Group (RTOG) study reported in 1980 compared three regimens: 40 Gy in 15 fractions; 30 Gy in ten fractions; and 20 Gy in five fractions.³⁴ The median survival in all three groups was between 3.2 months and 3.5 months ($P>0.05$). There is, therefore, no clear evidence that 20 Gy in five fractions is inferior to, or better than, 30 Gy in ten fractions (Level 1b).¹⁶

Other regimens assessed in RTOG randomised trials included: 10 Gy single-dose and 30–40 Gy in 10–20 fractions; 40 Gy in 20 fractions; 40 Gy in 15 fractions; 30 Gy in 15 fractions and 30 Gy in ten fractions.^{34,35} There was no statistically significant difference in median survival. The trial results suggest that regimens using only one or two fractions are inferior to 30 Gy in ten fractions, but that there is no improvement in survival when dose is increased beyond 30 Gy in ten fractions (Level 1b).¹⁶

Patients in RPA Class III have such a poor prognosis that it may be difficult to justify any radiation treatment at all. Careful consideration should be given to patients with non-small cell lung cancer. The Medical Research Council (MRC) QUARTZ study shows no significant benefit in terms of survival or quality adjusted life years for WBRT over optimal supportive care.³⁶

Recommendation

Multiple cerebral metastases:

30 Gy in 10 fractions over 2 weeks (Grade A)

20 Gy in 5 fractions over 1 week (Grade A)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-based Medicine.¹⁶

References

1. Gaspar L, Scott C, Rotman M *et al.* Recursive partitioning analysis (RPA) prognostic factors in three Radiation Therapy Oncology Groups (RTOG) brain metastases trials. *Int J Radiat Oncol Biol Phys* 1997; **37**(4): 745–751.
2. Gaspar L, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. *Int J Radiat Oncol Biol Phys* 2000; **47**(4): 1001–1006.
3. Lock M, Chow E, Pond GR *et al.* Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy? *Clin Oncol* 2004; **16**(5): 332–338.
4. Lutterbach J, Bartelt S, Stancu E, Guttenberger R. Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. *Radiother Oncol* 2002; **63**(3): 339–345.
5. Sperduto PW, Kased N, Roberge D *et al.* Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. *J Clin Oncol* 2012; **30**(4): 419–425.
6. Chamberlain MC, Silbergeld DL. Is graded prognostic assessment an improvement compared with radiation therapy oncology group's recursive partitioning analysis classification for brain metastases? *J Clin Oncol* 2012; **30**(26): 3315–3316; author reply 3316–3317.
7. Likhacheva A, Pinnix CC, Parikh NR *et al.* Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys* 2013; **85**(3): 656–661.
8. Nieder C, Andratschke NH, Geinitz H, Grosu AL. Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries. *Med Sci Monit* 2012; **18**(7): CR450–CR455.
9. Villà S, Weber DC, Moretones C *et al.* Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study. *Radiat Oncol* 2011; **6**: 23.
10. Sperduto PW, Yang TJ, Beal K, *et al.* Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). *JAMA Oncol.* 2017; **3**(6): 827–831.
11. Tsao MN, Lloyd NS, Wong RK. Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. *BMC Cancer* 2005; **5**: 34.
12. Mintz AH, Kestle J, Rathbone MP *et al.* A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. *Cancer* 1996; **78**(7): 1470–1476.
13. Noordijk EM, Vecht CJ, Haaxma-Reiche H *et al.* The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. *Int J Radiat Oncol Biol Phys* 1994; **29**(4): 711–717.
14. Patchell RA, Tibbs PA, Walsh JW *et al.* A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990; **322**(8): 494–500.
15. Andrews DW, Scott CB, Sperduto PW *et al.* Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet* 2004; **363**(9422): 1665–1672.
16. www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009 (last accessed 30/9/16)
17. Yamamoto M, Serizawa T, Shuto T *et al.* Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. *Lancet Oncol* 2014; **15**(4): 387–395.

References

18. Baschnagel AM, Meyer KD, Chen PY *et al.* Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. *J Neurosurg* 2013; **119**(5): 1139–1144.
19. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for four or more intracranial metastases. *Int J Radiat Oncol Biol Phys* 2006; **64**(3): 898–903.
20. Chen JC, Petrovich Z, O'Day S *et al.* Stereotactic radiosurgery in the treatment of metastatic disease to the brain. *Neurosurgery* 2000; **47**(2): 268–279; discussion 279–281.
21. Aoyama H, Shirato H, Tago M *et al.* Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA* 2006; **295**(21): 2483–2491.
22. Aoyama H, Tago M, Kato N *et al.* Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. *Int J Radiat Oncol Biol Phys* 2007; **68**(5): 1388–1395.
23. Chang EL, Wefel JS, Hess KR *et al.* Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol* 2009; **10**(11): 1037–1044.
24. Kocher M, Soffietti R, Abacioglu U *et al.* Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. *J Clin Oncol* 2011; **29**(2): 134–141.
25. Tsao MN, Lloyd N, Wong RK *et al.* Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. *Cochrane Database Syst Rev* 2012; **4**: CD003869.
26. Tsao MN, Rades D, Wirth A *et al.* Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. *Pract Radiat Oncol* 2012; **2**(3): 210–225.
27. Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. *Strahlenther Onkol* 1994; **170**(3): 155–161.
28. Brown PD, Ballmand KV, Cerhan JH *et al.* Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2017; **18**(8): 1049–1060.
29. Mahajan A, Ahmed S, McAleer MF *et al.* Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2017; **18**(8): 1040–1048.
30. Chatani M, Teshima T, Hata K *et al.* Whole brain irradiation for metastases from lung carcinoma. A clinical investigation. *Acta Radiol Oncol* 1985; **24**(4): 311–314.
31. Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. *Int J Radiat Oncol Biol Phys* 1977; **2**(11–12): 1091–1094.
32. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favourable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1981; **7**(7): 891–895.
33. Murray KJ, Scott C, Greenberg HM *et al.* A randomized phase III study of accelerated hyper-fractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. *Int J Radiat Oncol Biol Phys* 1997; **39**(3): 571–574.

References

34. Borgelt B, Gelber R, Kramer S *et al*. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1980; **6**(1): 1–9.
35. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1981; **7**(12): 1633–1638.
36. Mulvenna PM, Nankivell MG, Barton R *et al*. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. *Lancet* 2016; **388**(10055): 2004–2014..